2009. A renewed, ethical defense of placebo- controlled trials of new treatments for major depression and anxiety disorders. J Med Ethics 35: 384-389.Dunlop BW, Banja J. A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders. J Med...
Major depression is a severe psychiatric syndrome with very high prevalence and socioeconomic impact. Its pathophysiology is poorly known, yet several neurotransmitter systems and brain areas have been implicated. Selective serotonin (5-hydroxytryptamine [5(-HT)]) reuptake inhibitors (SSRIs) and seroton...
Clinicians, patients, and families are well aware of the pressing need for more effective treatments for depression, and this issue of the Journal is focused on new developments in the treatment of major depressive disorder. That major depression is a worldwide public health problem cannot be over...
JAMA Insights Women's Health November 27, 2023 Postpartum Depression—New Screening Recommendations and Treatments Tiffany A. Moore Simas, MD, MPH, MEd1,2; Anna Whelan, MD1,2; Nancy Byatt, DO, MS, MBA1,2 Author Affiliations JAMA. 2023;330(23):2295-2296. doi:10.1001/jama.20...
Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol. 2008;76(6):909-922. doi:10.1037/a0013075PubMedGoogle ScholarCrossref 7. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major ...
3). Outcome measurement tools have also become more diverse, which has enabled meaningful improvements in AD and the efficacy of treatments to be clearly determined in clinical trials. Overall, the field of AD clinical trials is evolving, and additional promising treatments for AD are likely to ...
Fresh insights into changes in the brain linked to depression could pave the way for new therapies. The study also sheds light on why a certain category ofantidepressant drugsstop working in some people. Researchers at the University of Edinburgh pinpointed a key molecule that may protect the ...
developed for Alzheimer's disease and Parkinson's disease, that reduce MAO-B levels, are well tolerated and could be used safely with other antidepressants," says Dr. Meyer. "Studying these medications in people with depression may uncover new treatments for people who don't respond to our com...
The lifetime prevalence of low back pain is 83%. Since there is a lack of evidence for therapeutic effect by cognitive behavioral therapy (CBT) or physical therapy (PT), it is necessary to develop objective physiological indexes and effective treatments.
Managing patients with treatment-resistant depression (TRD) remains a major challenge for the practicing physician. Depression is considered treatment-resistant when at least two adequate monotherapy trials with drugs from different pharmacologic classes fail to elicit a therapeutic response. Although determin...